Volume 85 Issue 4 | p. 18 | Concentrates
Issue Date: January 22, 2007

Merck, Archemix link for aptamers

Department: Business

Germany's Merck has signed a multiyear agreement with Archemix that focuses on the discovery of aptamer-based drugs to treat cancer. Cambridge, Mass.-based Archemix will receive an up-front payment and research funding of as much as $10 million. It could also receive milestone and royalty payments. Archemix says it has signed four aptamer partnerships over the past six months, including one recently with Pfizer (C&EN, Jan. 15, page 34)

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society